Welcome to our dedicated page for catb news (Ticker: catb), a resource for investors and traders seeking the latest updates and insights on catb stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect catb's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of catb's position in the market.
Astria Therapeutics, previously known as Catabasis Pharmaceuticals (NASDAQ:CATB), is focused on developing STAR-0215, a monoclonal antibody for hereditary angioedema, currently in preclinical stage. The company will begin trading under the new ticker symbol ATXS on September 9, 2021. Following its acquisition of Quellis, Astria raised approximately $110 million to further its mission of addressing rare and immunological diseases. As of June 30, 2021, it had $139.5 million in cash, anticipated to fund operations through 2023.
Catabasis Pharmaceuticals (NASDAQ: CATB) reported Q2 2021 financial results, showing a net loss of $7.5 million, improved from $9.5 million in Q2 2020. Cash reserves were $139.5 million, sufficient to support operations through 2023. R&D expenses decreased to $3.5 million from $6.8 million year-over-year, while G&A expenses increased to $4.0 million. The company aims to advance its lead drug, QLS-215, for chronic treatment of hereditary angioedema, with initial trial results expected by the end of 2022. A 1-for-6 reverse stock split will take effect on August 19, 2021.
Catabasis Pharmaceuticals (NASDAQ:CATB) announced that CEO Jill C. Milne, Ph.D., will present at the virtual Wedbush PacGrow Healthcare Conference on August 10, 2021, at 8:35 AM ET. The session titled “HAE There - Development Landscape in Hereditary Angioedema” will cover the treatment landscape for HAE, focusing on Catabasis's lead program, QLS-215, which is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development. A webcast of the session will be available for 30 days at the company’s website.
Catabasis Pharmaceuticals (NASDAQ:CATB) announced that CEO Jill C. Milne, Ph.D., will present an overview of the company and its lead program, QLS-215, at the virtual Ladenburg Thalmann Healthcare Conference on July 13, 2021, at 12:30 PM ET. QLS-215 is a monoclonal antibody inhibitor of plasma kallikrein, currently in preclinical development for hereditary angioedema. A webcast of the presentation can be accessed here and will be archived for 30 days.
Catabasis Pharmaceuticals (NASDAQ:CATB) announced that CEO Jill C. Milne, Ph.D., will present a corporate overview highlighting their lead program QLS-215, aimed at treating hereditary angioedema. This presentation will occur at two upcoming virtual investor conferences: the Oppenheimer Rare and Orphan Disease Summit on May 21, 2021, and the Jefferies Virtual Healthcare Conference on June 3, 2021, at 9:30 AM ET. Webcasts will be available for 30 days on the company's website.
Catabasis Pharmaceuticals (NASDAQ: CATB) reported its Q1 2021 financial results, highlighting a successful acquisition of Quellis and a substantial financing of approximately $110 million. The lead program QLS-215 aims to provide innovative treatment for hereditary angioedema, with clinical trials expected to commence in 2022. Key financial metrics include a cash position of $146.9 million and R&D expenses of $2.6 million, though the company also faced a significant net loss of $170.1 million due to acquired in-process research and development costs from the Quellis acquisition.
Catabasis Pharmaceuticals (NASDAQ:CATB) reported its financial results for Q4 and full year 2020, showing a net loss of $37.3 million or $2.03 per share, up from $26.3 million in 2019. The company acquired Quellis Biosciences, enhancing its pipeline with QLS-215, a monoclonal antibody for hereditary angioedema, expected to enter Phase 1 trials in 2022. Catabasis raised $110 million from a private placement, bolstering its cash position to approximately $104 million post-offering, with plans to fund operations through 2023.
Catabasis Pharmaceuticals (NASDAQ:CATB) announces CEO Jill C. Milne will present a corporate overview and details about their lead program, QLS-215, at upcoming virtual investor conferences. The H.C. Wainwright Global Life Sciences Conference will take place on March 9-10, 2021, with presentations available on-demand. Milne will also present at the Oppenheimer 31st Annual Healthcare Conference on March 18, 2021, at 10:00am ET. Additionally, Catabasis will participate in the Guggenheim Healthcare Talks on April 1, 2021. Webcasts for these events can be accessed via their website.
Catabasis Pharmaceuticals (NASDAQ:CATB) announced its acquisition of Quellis Biosciences, focusing on developing therapies for rare diseases. The acquisition was coupled with a private placement of Series X preferred stock, expected to raise roughly $110 million. This funding will primarily support the IND-enabling studies and clinical trials for QLS-215, targeting hereditary angioedema. Catabasis aims for an IND filing in H1 2022 and initiation of Phase 1 trials by late 2022. This strategic move is anticipated to create substantial value for stockholders.
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) reported disappointing results for its Phase 3 PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy, failing to meet primary and secondary endpoints. As a result, the company will cease development of edasalonexent and related trials. Financially, Catabasis ended Q3 2020 with $52.9 million in cash, down from $53.9 million in Q2. Net loss increased to $10.9 million, or $0.56 per share, compared to a net loss of $6.5 million for the same period last year. The company is exploring strategic options with financial advisor Ladenburg Thalmann.
